Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK

MT Newswires Live

03/24

Entrada Therapeutics (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.

The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.

Entrada said it is on course to begin the trial in Q3.

Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2521744366"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521744366\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521744366?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521744366","market":"fut","top_or_hot":-1,"title":"Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK","media":"MT Newswires Live","content":"<html><body><p> Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.</p><p>The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.</p><p>Entrada said it is on course to begin the trial in Q3.</p><p>Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-24 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.</p><p>The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.</p><p>Entrada said it is on course to begin the trial in Q3.</p><p>Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521744366","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521744366","pubTimestamp":1742815991,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Entrada Therapeutics  said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.Entrada said it is on course to begin the trial in Q3.Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","TRDA":"Entrada Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Entrada Therapeutics杜氏肌营养不良症研究治疗研究在英国获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRDA":1,"LENZ":1},"content_text":"Entrada Therapeutics (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.Entrada said it is on course to begin the trial in Q3.Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}